NES
AMAG

New England Securities’s AMAG Pharmaceuticals AMAG Stock Holding History

New England Securities’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$4K Hold
86
– – ﹤0.01% 1357
2014
Q3 		$3K Buy
+86
New +$1.83K ﹤0.01% 1438

Other funds holding AMAG

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
GCM
Greywolf Capital Management Purchase, New York $67.3M AUM 100.05% 1-Year Est. Return

New England Securities's AMAG Position: Q4 2014 in Review

New England Securities held its AMAG Pharmaceuticals (AMAG) position steady in Q4 2014 at 86 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1357.

New England Securities first reported a position in AMAG in Q3 2014 and has held it in 2 quarters since. 154 funds tracked by Wall St. Rank hold AMAG as of Q4 2014.

  • New England Securities held 86 shares of AMAG Pharmaceuticals worth $4K as of Q4 2014.
  • New England Securities left its AMAG Pharmaceuticals share count unchanged in Q4 2014.
  • AMAG Pharmaceuticals made up ﹤0.01% of New England Securities's portfolio in Q4 2014, its #1357 holding.
  • New England Securities first reported a position in AMAG Pharmaceuticals in Q3 2014 and has held it in 2 quarters since.
  • 154 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2014.

Based on New England Securities's 13F filing for Q4 2014, filed 26 Jan 2015.